Small molecule · Inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) · developed by Incyte
Ruxolitinib is a kinase inhibitor that blocks JAK1 and JAK2, which mediate signaling of cytokines and growth factors involved in hematopoiesis and immune function. It is studied in graft-versus-host disease, vitiligo, myelofibrosis, chronic myelomonocytic leukemia, and pyoderma gangrenosum.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jul 20, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06804811 | Phase 3 | NonSegmental Vitiligo | Recruiting | INCY |
| NCT06615050 | Phase 3 | Graft-versus-host Disease (GVHD) | Recruiting | INCY |
| NCT07783412 | Phase 2 | Pyoderma Gangrenosum | Recruiting | INCY |
| NCT07128381 | Phase 1/2 | Myelofibrosis (MF) | Recruiting | INCY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Myelomonocytic Leukemia (CMML)Graft-versus-host Disease (GVHD)Myelofibrosis (MF)NonSegmental VitiligoPyoderma Gangrenosum
Updated Nov 15, 2026. Something wrong or missing? Report it on the INCY page.
See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INCY catalysts and pipeline →